Yilin Xiong

Dr. Yilin Xiong


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2024 in International Journal of Surgery
Verified
Journal Article
Open access
PLPan Bs Liu
Pan Bs Liu
JMJiahao Meng
Jiahao Meng
HTHang Bs Tang
Hang Bs Tang
YXYifan Bs Xiao
Yifan Bs Xiao
XLXi Li
Xi Li
SGShuguang Gao
Shuguang Gao
Background: Total joint arthroplasty (TJA) alongside bariatric surgery (BS) is frequently operated on in obese arthritis patients. The controversy persists regarding BS before TJA, and the extent of its impact on the prognosis of TJA patients remains uncertain. To explore this, we conducted a meta-analysis. Methods: As of 1 October 2023, the latest search on PubMed, Cochrane Library, Embase, and Web of Science was conducted to compare outcomes between patients who underwent preoperative BS and those who did not. The analysis focused on parameters such as length of stay (LOS), infection risk, venous thromboembolism, revision, transfusions, dislocations, periprosthetic fractures, knee stiffness, medical complications, and all-cause mortality in the eligible studies. Results: This meta-analysis included 18 trials with a total of 292 196 patients. Pooled findings indicated that preoperative BS significantly shortened the LOS (MD, −0.16; 95% CI, −0.25 to 0.07; I 2 =58%; P =0.0004) and increased the risk of dislocation within 90 days (OR, 1.70; 95% CI, 1.20– 2 .42; I 2 =21%; P =0.003) and all-cause mortality within 30 days (OR, 3.69; 95% CI, 1.81–7.49; I 2 = 0%; P =0.0003) for TJA, in comparison with patients without BS. In the total hip arthroplasty (THA) subgroup, BS was more favorable, exhibiting significantly reduced risk of short-term revision (OR, 0.77; 95% C I , 0.61–0.99; I 2 =0%; P =0.04) and long-term infection (OR, 0.72; 95% CI, 0.61–0.85; I 2 =0%; P ≤0.0001). For total knee arthroplasty (TKA) patients, no significant benefit was identified. In addition, there was no statistically significant correlation between preoperative or postoperative BS and the occurrence of complications in TJA patients. Conclusions and Relevance: Compared with the control group without BS, preoperative BS can shorten the LOS, increase the risk of dislocation within 90 days and all-cause mortality within 30 days in TJA, and reduce the risk of specific surgical complications in the THA subgroup but shows no significant difference in the TKA subgroup. There are no differences in clinical outcomes whether BS is performed before or after TJA. More high-quality trials are needed to further clarify the impact of BS on obese patients undergoing TJA.

27 March 2024 in International Journal of Surgery
Verified
Journal Article
Open access
JMJiahao Meng
Jiahao Meng
HTHang B.S Tang
Hang B.S Tang
YXYifan B.S Xiao
Yifan B.S Xiao
WLWeijie B.S Liu
Weijie B.S Liu
YWYumei B.S Wu
Yumei B.S Wu
SGShuguang Gao
Shuguang Gao
Background: There was controversy surrounding the optimal thromboprophylaxis strategy for coronavirus disease 2019 (COVID-19) patients. This included debates on the dosage of anticoagulants for thromboembolism prophylaxis, the requirement for additional antiplatelet therapy, and the necessity of prophylaxis for outpatients and postdischarge. To explore this, the authors performed a meta-analysis of randomized controlled trials. Methods: PubMed, Cochrane Library, Embase, and Web of Science were last searched on 26 July 2023 for studies comparing the effect of different dose of anticoagulation, additional antiplatelet, and postdischarge prophylaxis for COVID-19 patients. The results of eligible studies were analyzed in terms of thromboembolism events, major bleeding and all-cause mortality during follow-up. Results: Our study included a total of 25 randomized controlled trials, involving 17 911 patients. Our results revealed that, compared to prophylactic dose, therapeutic dose showed lower thrombotic risk (RR, 0.66; 95% CI: 0.45–0.96) but had similar major bleeding risk for critically ill patients with COVID-19. On the other hand, intermediate dose and prophylactic dose demonstrated similar thromboembolism risk and major bleeding risk. For noncritically ill patients with COVID-19, therapeutic dose of anticoagulants was associated with lower thrombotic risk (RR, 0.50; 95% CI: 0.34–0.72) but, at the same time, increased the risk of major bleeding (RR, 2.01; 95% CI: 1.22–3.33). However, intermediate dose showed lower thromboembolism risk (RR, 0.38; 95% CI: 0.21–0.69) while maintaining a similar major bleeding risk. In critically ill patients, additional antiplatelet therapy showed similar thromboembolism, major bleeding risk, and mortality when compared to no treatment. For outpatients, additional prophylactic anticoagulation showed similar thromboembolism, major bleeding risk, and mortality when compared to no treatment. For postdischarge patients, postdischarge prophylaxis reduced thromboembolism risk (RR, 0.49; 95% CI: 0.31–0.76) but increased major bleeding risk (RR, 2.63; 95% CI: 1.13–6.14). Conclusion: For noncritically ill patients, therapeutic dose prophylactic anticoagulation significantly reduced venous thromboembolism but increases major bleeding risk. Intermediate dose effectively lowered venous thromboembolism without raising major bleeding risk. The optimal dose and need for additional antiplatelet therapy in critically ill patients, as well as the necessity of prophylactic anticoagulation in outpatient and postdischarge patients, required further investigation and confirmation through rigorous evidence studies.

26 May 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
YWYilun Wang
Yilun Wang
ZYZidan Yang
Zidan Yang
JWJing Wu
Jing Wu
DXDongxing Xie
Dongxing Xie
TYTuo Yang
Tuo Yang
YXYilin Xiong
Yilin Xiong

25 April 2025 in International Journal of Surgery
Verified
Journal Article
Open access
SGShuguang Gao
Shuguang Gao
JMJiahao Meng
Jiahao Meng
CZChao Zeng
Chao Zeng
JMJoan C. Monllau
Joan C. Monllau
RLRobert LaPrade
Robert LaPrade
GLGuang-Hua Lei
Guang-Hua Lei
Background: Posterior cruciate ligament (PCL) injury is a relatively common musculoskeletal condition. However, there is currently a lack of consensus on decision-making, treatment and postoperative management for such injuries. Objectives: To use the modified Delphi method to reach expert consensus on the management of PCL injury. Methods: A literature search of PubMed, Cochrane Library, Embase, and Web of Science for articles up to 17 October 2024, to support the development of recommendation statements. An Expert Panel of 90 experienced clinicians from orthopedics and sports medicine participated in a two-round Delphi process. Each statement was evaluated in two parts: the first part assessed content appropriateness (score of 7–9 indicating appropriateness and 4–6 indicating possible appropriateness), while the second part assessed agreement (score of 5–9 indicating agreement). Results: The panel members developed 11 statements using the Delphi process, addressing the following topics: (1) clinical decision-making, (2) treatment, and (3) postoperative management about PCL injuries. The final consensus was reached on 11 statements and we eventually translated these statements into a corresponding table of expert recommendations. Conclusion: Consensus was reached on 11 statements regarding three aspects of PCL injury management. These findings provide a foundation for developing evidence-based guidelines that can enhance clinical decision-making, improve treatment strategies, and optimize postoperative care for patients with PCL injuries.

29 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
WLWeijie Liu
Weijie Liu
HWHaoChen Wang
HaoChen Wang
CSChao Su
Chao Su
SKShida Kuang
Shida Kuang
YXYilin Xiong
Yilin Xiong
SGShuguang Gao
Shuguang Gao
Objective. To evaluate the efficacy and safety of oral colchicine in the treatment for knee OA. Design. Meta‐analysis. Data Sources. Embase, PubMed (MEDLINE), the Cochrane Library, and Web of Science from inception to December 12, 2021. Study Selection. RCTs comparing colchicine with placebo for knee OA were included. No language or date restrictions were applied. Two authors abstracted data and determined quality. Outcomes of interest included VAS‐pain, WOMAC total index, and patient‐reported adverse events. Results. A total of five RCTs including 400 adult patients with OA met the inclusion criteria. The mean age of patients included was 56.05 years (range 21 to 79), and 80.87% were female. There was no difference in VAS‐pain (MD ‐1.49; 95% CI ‐3.15, 0.17; p = 0.08) when compared colchicine group with placebo group. And there was no statistically difference in WOMAC total index (std. MD ‐0.13; 95% CI ‐0.64, 0.38; p = 0.61) and patient report adverse events (RR 1.23; 95% CI 0.72, 2.11; p = 0.46). Conclusion. Colchicine is not currently recommended as a treatment for knee OA but might have insignificant effect. The conclusion is limited due to the variation in assessment indicator among available data. Further RCTs with larger sample size and longer follow‐up are needed to confirm the findings.

20 July 2019 in Clinical Rheumatology
Verified
Journal Article
Closed access
ZYZidan Yang
Zidan Yang
GLGuanghua Lei
Guanghua Lei
XLXiaoxiao Li
Xiaoxiao Li
YWYilun Wang
Yilun Wang
ZXZikun Xie
Zikun Xie
TYTubao Yang
Tubao Yang